Welcome to our dedicated page for Innate Pharma Sa SEC filings (Ticker: IPHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innate Pharma S.A. (IPHA) SEC filings page on Stock Titan provides access to the company’s US regulatory submissions, primarily filed as a foreign private issuer on Form 6-K and Form 20-F-related documents. Innate Pharma is a global, clinical-stage biotechnology company developing antibody-based immunotherapies for cancer, with securities listed on Euronext Paris (IPH) and Nasdaq (IPHA).
Through these filings, Innate Pharma reports information that supplements its press releases and investor communications. Form 6-K reports typically furnish press releases on topics such as business updates, clinical trial progress, financial results, changes in capital structure, and key corporate developments. Some 6-K filings are incorporated by reference into Innate Pharma’s registration statements on Form F-3 and Form S-8, which relate to securities offerings and equity compensation plans.
For a company focused on immuno-oncology and antibody-engineering, SEC filings can provide additional detail on collaboration and licensing agreements with partners such as Sanofi and AstraZeneca, risk factor discussions, and descriptions of pipeline assets including IPH4502, lacutamab, monalizumab and ANKET®-based programs. Filings may also include information on share capital, voting rights, financing tools such as at-the-market programs, and other capital markets activities.
On Stock Titan, these documents are complemented by AI-powered summaries designed to help readers quickly understand the key points of lengthy filings. Users can review new Form 6-K submissions as they are furnished to the SEC’s EDGAR system, and use the summaries to navigate complex regulatory language, while still having access to the full original documents for detailed analysis.
Innate Pharma S.A. filed a Form 6-K to share details of an upcoming conference call and webcast for its full year 2025 financial results. The call will take place on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of results for the year ended December 31, 2025.
Senior leadership, including the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Chief Financial Officer and Vice President of Investor Relations, will participate. The event will be accessible via webcast and telephone, with a replay available on the company’s website for 90 days.
Innate Pharma SA ownership update: Novo Nordisk A/S reports beneficial ownership of 7,333,778 ordinary shares, representing 7.82% of the class as of 12/31/2025. The filing shows sole voting and dispositive power over 7,333,778 shares.
The form is an amended Schedule 13G/A filed and signed on 03/04/2026 by Karsten Munk Knudsen, Chief Financial Officer.
Innate Pharma S.A. filed a report noting that its executive team will take part in the Leerink Partners Global Healthcare Conference 2026 in Miami from March 8–11. The company will host a fireside chat on March 9 at 3:40 PM ET, with a live webcast and replay available through the Investors section of its website.
The filing also highlights Innate Pharma’s focus on developing next-generation antibody-based immunotherapies for cancer, including IPH4502, lacutamab and monalizumab, and mentions ongoing collaborations with major partners such as AstraZeneca and Sanofi.
Innate Pharma SA filed an amended ownership report showing that AstraZeneca PLC and its wholly owned subsidiary MedImmune Limited together beneficially own 7,825,501 Ordinary Shares, including 1,565,001 shares represented by ADSs. This stake represents 8.3% of Innate Pharma’s Ordinary Shares, based on 93,719,323 shares outstanding as of December 31, 2025, as disclosed in a recent Form 6-K. AstraZeneca PLC and MedImmune Limited are each deemed to have sole voting and dispositive power over all shares held by MedImmune Limited, and neither the reporting entities nor their listed directors and officers have traded Innate Pharma shares in the past 60 days.
Innate Pharma S.A. reports its capital and voting structure as of December 31, 2025. The Company had 93,719,323 ordinary shares outstanding, along with 6,324 Preferred Shares 2016 and 7,581 Preferred Shares 2017. Based on French market rules, Innate calculates a total of 94,484,443 theoretical voting rights, which includes all shares with attached voting rights, even those suspended, and incorporates voting rights from AGAP 2016. The number of exercisable voting rights, which excludes treasury shares with suspended rights, was 94,465,868. The Company also highlights its focus on developing next-generation immunotherapies for cancer and notes collaborations with major partners such as AstraZeneca and Sanofi.